Hypera publishes 2Q26 earnings presentation
Reuters2026/08/07 11:48- Hypera published its 2Q26 earnings presentation on Aug. 7, 2026.
- Net revenue rose 8.5% to R$ 2.34 billion. Gross margin was 61.3%, up 1.7 pp.
- EBITDA from continuing operations increased 4.1% to R$ 754.5 million. Net earnings from continuing operations rose 15% to R$ 450 million.
- Operating cash flow was 103.5% of EBITDA. Interest on capital was approved at R$ 135.2 million.
- Highlights cited ANVISA approval of Semavy injectable semaglutide. The release also flagged a partnership in non-hormonal menopausal symptom treatment.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Electra Therapeutics (ETRA.US) submits US IPO application, leveraging the biotech IPO boom to advance new drug development for immune diseases and cancer.
Electra Therapeutics Inc. has officially filed for an initial public offering (IPO), aiming to leverage the strong IPO performance of the biotechnology sector this year to raise funds for its clinical-stage pipeline of drugs targeting immune-mediated diseases and cancer.
Fogo Foundation Attacked, Approximately 400 Million FOGO Tokens Transferred
Blue Owl (OWL.US) teams up with PIMCO to tailor a $2.4 billion GPU financing for IREN (IREN.US)
A $2.4 billions debt financing round, led by funds under Blue Owl Capital Inc., has been finalized. The funds will be allocated to cloud service provider IREN Ltd. to purchase NVIDIA's Blackwell Ultra GPUs, supporting the development of its data center campus in Canada.
Crypto prices
More
